Dalfaz

Dalfaz is an alpha1-blocker, a drug used in benign prostatic hyperplasia to eliminate urinary disorders.

Release form and composition

Dalfaz tablets produce 2.5 mg of alfuzosin hydrochloride. Also released tablets Dalfaz retard and Dalfaz CP with a content of 5 and 10 mg of the active substance, respectively.

The drug is sold in blisters of 10 and 14 tablets.

Indications for use

According to the instructions, Dalfaz is indicated for use in:

• The presence of functional symptoms of benign prostatic hyperplasia in case of inexpediency of surgical intervention;
• Acute urinary retention due to benign prostatic hyperplasia (as an adjunctive therapy).

Contraindications

According to the instructions, Dalfaz should not be taken in the following cases:

• Intestinal obstruction;
• Orthostatic hypotension;
• Hypersensitivity to the active or auxiliary components of the drug;
• Severe renal failure (CC less than 30 ml per minute);
• Severe abnormal liver and / or kidney function.

Dalfaz children and women do not use. With caution, medication prescribed for coronary heart disease and angina, as well as men over the age of 75 years.

Dosing and Administration

Dalfaz should be taken after meals. The exact dose of the drug and the duration of use are determined individually by the attending physician, depending on the severity of the symptoms and the effectiveness of the therapy. As a rule, the medication is prescribed three times a day at a dose of 2.5 mg. If necessary, the daily dosage can be increased to 10 mg three times a day, but only gradually. Men over 65 years old are prescribed 2.5 mg twice a day. In this case, the interval between taking the medication should not be less than 12 hours.

The drug Dalfaz CP is prescribed 1 tablet (10 mg) once a day, if your doctor does not provide another dosage regimen. In the case of catheter use, the medication is taken in a dose of 10 mg for 3-4 days, starting from the first day of catheterization. Thus, treatment with Dalfaz CP lasts 2-3 days on the background of the catheter and another day after its removal.

Side effects

The use of Dalfaz can cause the following side effects from various systems of vital activity of the organism:

• Epigastric pain;
• Nausea;
• Edema;
• Sternum pain;
• Itching;
• Diarrhea;
• Headache;
• Malaise;
• Drowsiness;
• Dizziness;
• Tachycardia;
• Orthostatic hypotension;
• Skin rashes;
• Dry mouth.

In the case of long-term use of Dalfaza in high doses, significantly higher than the recommended, patients may develop a strong reduction in blood pressure. When this symptom of overdose appears, it is recommended to immediately seek professional medical assistance.

Treatment of overdose should be carried out in the hospital with the use of measures aimed at increasing the volume of circulating blood and the appointment of high-molecular substances and vasoconstrictor drugs.

special instructions

Preparations Dalfaz retard and Dalfaz CP have a prolonged effect. When applying them, the tablet should be swallowed whole, as a violation of the integrity can lead to improper release of the active ingredient, and, accordingly, cause unwanted side reactions.

In some patients, in particular, undergoing treatment with antihypertensive drugs, the development of postural hypotension, often accompanied by increased sweating, severe dizziness and loss of strength, is not excluded. In this case, the patient should take a horizontal position and wait until the above symptoms disappear. Such reactions are mainly temporary, occur at the beginning of Dalfaz therapy and pass quickly, so they are not a reason to discontinue the drug. However, every patient who is prescribed Dalfaz should be warned about such reactions.

The use of Dalfaz in coronary insufficiency is recommended only in combination with drugs for the treatment of this disease. If the patient’s strokes do not go away or become more pronounced, Dalfaz therapy should be stopped.

Patients should also be aware that at the beginning of drug therapy, reactions such as dizziness, blurred vision, asthenia may occur. Therefore, during Dalfaz therapy, it is necessary to manage with great care potentially dangerous mechanisms that require high concentration of attention.

The simultaneous use of Dalfaz with drugs that lower blood pressure, especially with calcium channel blockers, is not recommended, as this may lead to the development of arterial hypotension and cause the development of collapse.

In the case of a combination of Dalfaz with inhibitors of the CYP3A4 system, such as itraconazole, ritonavir, ketoconazole, an increase in the serum level of alfuzosin in the blood is not excluded.

Pharmaceutical Dalfaz is not compatible with other alpha1-blockers.

Patients who are to undergo surgery or a diagnostic procedure using anesthesia should warn the attending physician that they are taking Dalfas, as it may cause the development of unstable blood pressure.

Analogs

Structural analogues of Dalfaz are Alfuprost MR and Alfuzosin.

Drugs that have similar pharmacological effects are:

• Omnick;
• Taniz;
• Tulosin;
• Fokusin;
• Sonizin;
• Omsulozin;
• Revocarine;
• Proflolsin;
• Tamzelin;
• Urorek;
• Tamsulosin.

Terms and conditions of storage

According to the instructions, Dalfaz stored in a dry, cool, dark place out of the reach of children. Shelf life of the drug is 3 years.